MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Atara Biotherapeutics Total Liabilities 2011-2026 | ATRA
Annual Total Liabilities Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 M | 206 M | 265 M | 250 M | 189 M | 126 M | 52.2 M | 53 M | 39.9 M | 10.2 M | 9.88 M | 2.94 M | 62.8 M | 8.02 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 265 M | 2.94 M | 95.2 M |
Quarterly Total Liabilities Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.8 M | 71.9 M | 117 M | 206 M | 233 M | 228 M | 264 M | 265 M | 240 M | 239 M | 237 M | 250 M | 181 M | 179 M | 173 M | 189 M | 140 M | 125 M | 131 M | 126 M | 126 M | 126 M | 126 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 53 M | 53 M | 53 M | 53 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 1.75 M | 1.75 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 265 M | 1.75 M | 96.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 221.14 | 2.6 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
2.24 M | $ 2.37 | 1.72 % | $ 3.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 19.6 | 1.92 % | $ 916 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
68.8 M | - | -3.03 % | $ 260 M | USA |
 |
Phathom Pharmaceuticals
PHAT
|
697 M | $ 10.35 | 2.88 % | $ 755 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
1.34 M | $ 1.27 | 4.09 % | $ 7.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.35 | 1.89 % | $ 344 M | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
20.7 M | $ 8.23 | 0.61 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 47.4 | 2.09 % | $ 4.26 B |  Schweiz |
 |
Cyclacel Pharmaceuticals
CYCC
|
6.27 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Pliant Therapeutics
PLRX
|
44 M | $ 1.32 | 3.13 % | $ 81 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
11.8 M | $ 1.39 | -0.36 % | $ 73 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
29.6 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
72.7 M | $ 3.26 | 4.49 % | $ 251 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
63.4 M | $ 1.53 | 2.35 % | $ 99.5 M |  Niderland |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.51 | 4.76 % | $ 864 M | Canada |
 |
Homology Medicines
FIXX
|
19.8 M | - | 0.77 % | $ 53.4 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |